Compare stocks

Abivax Société Anonyme is a clinical-stage biotechnology company headquartered in Paris, France, with a research center in Montpellier and a U.S. office in Waltham, Massachusetts. Founded in December 2013, the company focuses on developing therapeutics that modulate the immune response to treat chronic inflammatory diseases. Its lead drug candidate, obefazimod (formerly ABX464), is in Phase 3 clinical trials for moderately to severely active ulcerative colitis and is being prepared for a Phase 2a trial in Crohn's disease. Abivax collaborates closely with the French National Center for Scientific Research (CNRS), the Institut Curie, and the University of Montpellier. In 2015, the company raised €57.7 million in its initial public offering on Euronext Paris, and in October 2023, it raised €232.3 million through an IPO on the Nasdaq Global Market.

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.